글로벌 레버 선천성 아마우로시스 시장 – 2029년까지의 산업 동향 및 예측

보고서 사용자 지정 보고서 사용자 지정 지금 구매 지금 구매 무료 샘플 보고서 무료 샘플 보고서
집 Pharmaceutical Global Leber Congenital Amaurosis Market
TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

글로벌 레버 선천성 아마우로시스 시장 – 2029년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Apr 2022
  • Global
  • 350 Pages
  • 테이블 수: 638
  • 그림 수: 66
지금 구매 지금 구매

>질병 유형(유아형, 청소년형 및 기타), 유형(치료 및 진단), 최종 사용자(병원, 전문 클리닉, 외래 수술 센터, 가정 의료 및 기타), 유통 채널(직접 입찰 및 소매 판매)별 글로벌 레버 선천성 흑내장 시장 산업 동향 및 2029년까지의 예측.

레버 선천성 아마우로시스 시장

 시장 분석 및 통찰력

글로벌 레버 선천성 아마우로시스 시장은 당뇨병 및 위장 장애와 같은 만성 질환의 유병률 증가, 신생 기업의 증가, 가정 간병 서비스에서 주입 펌프의 인기와 같은 요인에 의해 주도되고 있으며, 이는 수요를 증가시키고 연구 개발에 대한 투자 증가로 이어지며 시장 성장으로 이어집니다. 현재 다양한 연구 조사가 진행 중이며, 이는 제조업체가 새롭고 혁신적인 레버 선천성 아마우로시스 치료법과 요법을 개발할 수 있는 경쟁 우위를 창출할 것으로 예상되며, 이는 레버 선천성 아마우로시스 시장에서 다양한 다른 기회를 제공할 것으로 예상됩니다. 그러나 주입 요법 중 승인 및 장치 오류에 대한 엄격한 정부 규정은 성장을 방해할 것으로 예상됩니다.

레버 선천성 아마우로시스 시장

레버 선천성 아마우로시스 시장

글로벌 레버 선천성 아마우로시스 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다. 다양한 지역의 개발도상국에 있는 소매점의 확장성과 사업 확장, 기계 및 약물 제품의 안전한 유통을 위한 공급업체와의 파트너십은 예측 기간 동안 시장 수요를 촉진한 주요 원동력입니다.

글로벌 레버 선천성 아마우로시스 시장은 지지적이며 질병의 진행을 줄이는 것을 목표로 합니다. Data Bridge Market Research는 글로벌 레버 선천성 아마우로시스 시장이 2022년에서 2029년까지의 예측 기간 동안 4.8%의 CAGR로 성장할 것이라고 분석합니다.

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 연도

2020 (2019-2014까지 사용자 정의 가능)

양적 단위

수익은 백만 달러, 가격은 미화로 표시됨

다루는 세그먼트

질병 유형(유아형, 청소년형 및 기타), 유형(치료, 진단), 최종 사용자(병원, 전문 클리닉, 외래 수술 센터 , 가정 의료 및 기타), 유통 채널(직접 입찰 및 소매 판매) 별

적용 국가

By Country (U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa)

Market Players Covered

Invitae Corporation, Spark Therapeutics, Inc., LKC Technologies, CENTOGENE N.V., Optos, Metrovision, Blue Print Genetics Oy (A Subsidiary of Quest Diagnostics), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio, Inc. , Atsena Therapeutics, Editas Medicine, Eluminex Biosciences, Okuvision, Astellas Pharma Inc., Allergan, agtc, Gyroscope Therapeutics Limited, SparingVision, Kubota Pharmaceutical Holdings Co. Ltd., REGENXBIO Inc. among others

Global Leber Congenital Amaurosis Market Dynamics

Drivers

  • Increase in incidence and prevalence of rpe65 gene-mediated in retinal diseases

Inherited retinal dystrophies (IRDs) represent a genetically diverse group of progressive, visually debilitating diseases. Adult and pediatric patients with vision loss due to IRD caused by biallelic mutations in the 65-kDa retinal pigment epithelium (RPE65) gene are often clinically diagnosed as retinitis pigmentosa (RP), and leber congenital amaurosis (LCA).

Leber congenital amaurosis (LCA) is an eye disorder that primarily affects the retina. LCA is characterized by severe visual impairment from birth or the first few months of life, roving eye movements or nystagmus, poor pupillary light responses, oculo digital sign (poking, rubbing, and/or pressing of the eyes), and undetectable or severely abnormal full-field electroretinogram (ERG). LCA is usually inherited as an autosomal recessive genetic condition.

  • Increase in pipeline products and clinical trials

The continuous innovation for the treatment of inherited retinal diseases and leber congenital amaurosis disorder has the potential to positively impact the market as the size of the market will increase, when these products will have approved in the global market. Due to no pharmacological treatments for the LCA the major market players are continuously innovating the treatment or investing in the R&D for the treatment. Various ongoing clinical trials are recruiting worldwide to find the mechanism of diseases for treatment.

레버 선천성 아마우로시스 시장

Opportunities

  •  Increase in government initiatives toward leber congenital amaurosis

According to WHO, the prevalence of monogenic IRDs is it affects about 1 in 40,000 newborns globally. To prevent these, the government of several countries across the globe have taken initiatives.

The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the global leber congenital amaurosis market.

Restraints/Challenges

The cost of the product plays a major factor in the market. In the inherited retinal diseases market, it is generally observed that the cost of the products is highly sophisticated, need to be precise, and other specifications increase the product's cost.

The high cost of the treatment is due to the various checkpoints of the treatment along with the use of high-tech modalities to perform such treatment procedures.

However, the hospital care further adds to the cost of the leber congenital amaurosis. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with leber congenital amaurosis treatment and diagnosis is expected to restrain the global leber congenital amaurosis market growth.

Whereas the European Medicines Agency does not. Gene therapy products are regulated by FDA’s Center for Biologics Evaluation and Research (CBER). FDA requires the submission of an IND before initiating clinical studies, and an approved biologics license application (BLA) to market the product in the United States. The regulatory framework for the development and manufacturing of gene therapy products comprises reg­ulations and guidance documents, including the interpretation of these governing documents by regulators.

However, every country is bounded by the guidelines regulated by different authorities which are expected to act as a challenge to the growth of the global leber congenital amaurosis market.

Recent Developments

  • In September 2021, Gyroscope Therapeutics Limited clinical-stage gene therapy company focused on diseases of the eye, announced positive interim data from the ongoing open-label Phase I/II clinical trial of its investigational one-time gene therapy, GT005, in people with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • In January 2020, Allergan launched SkinMedica Instant Bright Eye Cream, a refreshing eye treatment that hydrates, brightens, and helps visibly firm the appearance of the delicate skin around the eyes. The product is designed to immediately improve the appearance of the eyes and continues reducing the visible signs of aging and fatigue over time including dark circles, fine lines, and creepiness of upper eyelids.

Global Leber Congenital Amaurosis Market Segmentation

Global leber congenital amaurosis market is categorized into disease type, type, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Disease Type

  • Infantile Type
  • Juvenile Type
  • Others

On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type & others

Type

  • Diagnosis
  • Therapy

On the basis by type, the global leber congenital amaurosis market is segmented into diagnosis and therapy. Diagnosis segment is further segmented into clinical diagnosis and genetic diagnosis. Clinical diagnosis is further segmented into clinical eye examination, visual field test, retail imaging, and electro physiological tests. Clinical diagnosis is sub-segmented into electrophysiological tests, retinal imaging, visual field test and clinical eye examination. Electrophysiology tests is subsegmented into full-field electroretinogram (ERG) and dark adaptometry (DA). Retinal imaging is subsegmented into optical coherence tomography (OCT), fundus autofluorescence imaging (FAF), scanning laser ophthalmoscopy (SLO) and adaptive optics (AO) imaging and conventional color fundus imaging. Visual field tests is sub-segmented into computerized visual field tests and manual field test. Clinical examination is sub-segmented into slit lamp, indirect ophthalmoscopy, refraction test and dilation exam. Therapy segment is further segmented into gene therapy, retinal therapy, neuroprotective agents, and others. Gene therapy is further segmented into luxturna and others. Neuroprotective agents are further segmented into vitamin A palmitate, docosahexaenoic acid (DHA), lutein, and others.

End User

  • Hospitals
  • Specialty clinics
  • Ambulatory surgical centers
  • Home healthcare
  • Others

On the basis of end user, the global leber congenital amaurosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others.

Distribution Channel

  • Retail Sales
  • Direct Tender

레버 선천성 아마우로시스 시장

On the basis of distribution channel, the global leber congenital amaurosis market is segmented into retail sales, direct tender.

Leber Congenital Amaurosis Market Regional Analysis/Insights

The leber congenital amaurosis market is analyzed and market size insights and trends are provided by country, disease type, type, end user, and distribution channel as referenced above.

The countries covered in the leber congenital amaurosis market report are U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa.

Europe is expected to dominate due to increase in technological advancement in the developing areas.

레버 선천성 아마우로시스 시장

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규제의 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 추세 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.   

경쟁 환경 및 레버 선천성 아마우로시스 시장 분석

글로벌 레버 선천성 아마우로시스 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우세입니다. 위에 제공된 데이터 포인트는 레버 선천성 아마우로시스 시장에 대한 회사의 초점과만 관련이 있습니다.

Invitae Corporation, Spark Therapeutics, Inc., LKC Technologies, CENTOGENE NV, Optos, Metrovision, Blue Print Genetics Oy(Quest Diagnostics의 자회사), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio, Inc., Atsena Therapeutics, Editas Medicine, Eluminex Biosciences, Okuvision, Astellas Pharma Inc., Allergan, agtc, Gyroscope Therapeutics Limited, SparingVision, Kubota Pharmaceutical Holdings Co. Ltd., REGENXBIO Inc. 등이 있습니다.

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가 전화를 요청하십시오.

 

SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

Sample Image Click on image to enlarge
  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL LEBER CONGENITAL AMAUROSIS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 DISEASE TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PIPELINE ANALYSIS FOR GLOBAL LEBER CONGENTIAL AMAUROSIS MARKET

4.2 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS

4.3 PESTEL ANALYSIS

4.4 PORTERS FIVE FORCES

5 EPIDEMIOLOGY

6 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES

6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS

6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER

 

6.2 RESTRAINTS

6.2.1 LACK OF QUALIFIED PROFESSIONALS

6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE

6.3 OPPORTUNITIES

6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS

6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE

6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT

6.4 CHALLENGES

6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY

6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS

7 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE

7.1 OVERVIEW

7.2 INFANTILE TYPE

7.3 JUVENILE TYPE

7.4 OTHERS

8 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE

8.1 OVERVIEW

8.2 THERAPY

8.2.1 GENE THERAPY

8.2.1.1 LUXTURNA

8.2.2 RETINAL PROSTHETIC

8.2.3 NEUROPROTECTIVE AGENTS

8.2.3.1 VITAMIN A PALMITATE

8.2.3.2 DOCOSAHEXAENOIC ACID

8.2.3.3 LUTEIN

8.2.3.4 OTHERS

8.2.4 OTHERS

8.3 DIAGNOSIS

8.3.1 CLINICAL DIAGNOSIS

8.3.1.1 ELECTROPHYSIOLOGICAL TESTS

8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG)

8.3.1.1.2 DARK ADAPTOMETRY (DA)

8.3.1.2 RETINAL IMAGING

8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT)

8.3.1.2.2 FUNDUS AUTOFLUORESCENCE

8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO)

8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING

8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING

 

8.3.1.3 VISUAL FIELD TEST

8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS

8.3.1.3.2 MANUAL FIELD TEST

8.3.1.4 CLINICAL EYE EXAMINATION

8.3.1.4.1 SLIT LAMP

8.3.1.4.2 INDIRECT OPHTHALMOSCOPY

8.3.1.4.3 REFRACTION TEST

8.3.1.4.4 DILATION EXAM

8.3.1.5 OTHERS

8.3.2 GENETIC DIAGNOSIS

9 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER

9.1 OVERVIEW

9.2 HOSPITALS

9.3 SPECIALITY CLINICS

9.4 AMBULATORY SURGICAL CENTERS

9.5 HOME HEALTHCARE

9.6 OTHERS

10 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW

10.2 RETAIL SALES

10.2.1.1 HOSPITAL PHARMACIES

10.2.1.2 RETAIL PHARMACIES

10.2.1.3 OTHERS

10.3 DIRECT TENDER

11 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY REGION

11.1 OVERVIEW

11.2 NORTH AMERICA

11.2.1 U.S.

11.2.2 CANADA

11.2.3 MEXICO

 

11.3 EUROPE

11.3.1 GERMANY

11.3.2 FRANCE

11.3.3 U.K.

11.3.4 RUSSIA

11.3.5 ITALY

11.3.6 SPAIN

11.3.7 NETHERLAND

11.3.8 SWITZERLAND

11.3.9 POLAND

11.3.10 TURKEY

11.3.11 AUSTRIA

11.3.12 HUNGARY

11.3.13 NORWAY

11.3.14 IRELAND

11.3.15 LITHUANIA

11.3.16 REST OF EUROPE

11.4 ASIA-PACIFIC

11.4.1 CHINA

11.4.2 JAPAN

11.4.3 INDIA

11.4.4 SOUTH KOREA

11.4.5 AUSTRALIA

11.4.6 SINGAPORE

11.4.7 THAILAND

11.4.8 INDONESIA

11.4.9 PHILIPPINES

11.4.10 MALAYSIA

11.4.11 VIETNAM

11.4.12 REST OF ASIA-PACIFIC

11.5 SOUTH AMERICA

11.5.1 BRAZIL

11.5.2 ARGENTINA

11.5.3 PERU

11.5.4 REST OF SOUTH AMERICA

 

11.6 MIDDLE EAST AND AFRICA

11.6.1 SOUTH AFRICA

11.6.2 SAUDI ARABIA

11.6.3 U.A.E

11.6.4 ISRAEL

11.6.5 EGYPT

11.6.6 KUWAIT

11.6.7 REST OF MIDDLE EAST AND AFRICA

12 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: GLOBAL

12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

12.3 COMPANY SHARE ANALYSIS: EUROPE

12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 SPARK THERAPEUTICS, INC

14.1.1 COMPANY SNAPSHOT

14.1.2 COMPANY SHARE ANALYSIS

14.1.3 PRODUCT PORTFOLIO

14.1.4 RECENT DEVELOPMENT

14.1.4.1 EU AUTHORIZATION

14.2 OPTOS

14.2.1 COMPANY SNAPSHOT

14.2.2 COMPANY SHARE ANALYSIS

14.2.3 PRODUCT PORTFOLIO

14.2.4 RECENT DEVELOPMENT

14.2.4.1 PRODUCT APPROVAL

14.3 CD GENOMICS

14.3.1 COMPANY SNAPSHOT

14.3.2 COMPANY SHARE ANALYSIS

14.3.3 PRODUCT PORTFOLIO

14.3.4 RECENT DEVELOPMENT

14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS)

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.4.5.1 COLLABORATION

14.5 LKC TECHNOLOGIES, INC

14.5.1 COMPANY SNAPSHOT

14.5.2 COMPANY SHARE ANALYSIS

14.5.3 PRODUCT PORTFOLIO

14.5.4 RECENT DEVELOPMENT

14.5.4.1 PRODUCT APPROVAL

14.5.5 PRODUCT APPROVAL

14.6 AGTC

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENTS

14.6.4.1 AGREEMENT

14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENTS

14.8 ASTELLAS PHARMA INC.

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENT

14.9 ATSENA THERAPEUTICS

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.1 CENTOGENE N.V.

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENT

14.10.4.1 PRODUCT LAUNCH

14.11 COAVE THERAPEUTICS

14.11.1 COMPANY SNAPSHOT

14.11.2 PRODUCT PORTFOLIO

14.11.3 RECENT DEVELOPMENT

 

14.12 EDITAS MEDICINE

14.12.1 COMPANY SNAPSHOT

14.12.2 REVENUE ANALYSIS

14.12.3 PRODUCT PORTFOLIO

14.12.4 RECENT DEVELOPMENTS

14.12.4.1 DATA & TRAIL DATA PRESENTATION

14.13 ELUMINEX BIOSCIENCES

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 GYROSCOPE THERAPEUTICS LIMITED

14.14.1 COMPANY SNAPSHOT

14.14.2 PRODUCT PORTFOLIO

14.14.3 RECENT DEVELOPMENTS

14.15 INVITAE CORPORATION

14.15.1 COMPANY SNAPSHOT

14.15.2 REVENUE ANALYSIS

14.15.3 PRODUCT PORTFOLIO

14.15.4 RECENT DEVELOPMENTS

14.15.4.1 NEW FACILITY

14.15.4.2 EXPANSION

14.16 IVERIC BIO.

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENT

14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENTS

14.18 MEIRAGTX LIMITED

14.18.1 COMPANY SNAPSHOT

14.18.2 PRODUCT PORTFOLIO

14.18.3 RECENT DEVELOPMENT

14.19 METROVISION

14.19.1 COMPANY SNAPSHOT

14.19.2 PRODUCT PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.19.3.1 FDA CLEARANCE APPROVAL

 

14.2 OCUGEN INC.

14.20.1 COMPANY SNAPSHOT

14.20.2 PRODUCT PORTFOLIO

14.20.3 RECENT DEVELOPMENT

14.21 OKUVISION

14.21.1 COMPANY SNAPSHOT

14.21.2 PRODUCT PORTFOLIO

14.21.3 RECENT DEVELOPMENTS

14.21.3.1 APPROVAL

14.22 PROQR THERAPEUTICS

14.22.1 COMPANY SNAPSHOT

14.22.2 PRODUCT PORTFOLIO

14.22.3 RECENT DEVELOPMENTS

14.23 REGENXBIO INC.

14.23.1 COMPANY SNAPSHOT

14.23.2 REVENUE ANALYSIS

14.23.3 PRODUCT PORTFOLIO

14.23.4 RECENT DEVELOPMENTS

14.24 SPARINGVISION

14.24.1 COMPANY SNAPSHOT

14.24.2 PRODUCT PORTFOLIO

14.24.3 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

표 목록

TABLE 1 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 2 GLOBAL INFANTILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 GLOBAL JUVENILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 GLOBAL OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 GLOBAL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 GLOBAL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 8 GLOBAL GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 GLOBAL NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 10 GLOBAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 GLOBAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 12 GLOBAL CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 13 GLOBAL ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 GLOBAL RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 GLOBAL VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 GLOBAL CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 18 GLOBAL HOSPITALS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 GLOBAL SPECIALITY CLINICS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 GLOBAL AMBULATORY SURGICAL CENTERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 GLOBAL HOME HEALTHCARE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 GLOBAL OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 24 GLOBAL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 GLOBAL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 26 GLOBAL DIRECT TENDER IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)

TABLE 29 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 43 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 44 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 45 U.S. THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 46 U.S. GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 47 U.S. NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 U.S. DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 U.S. CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 U.S. RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 U.S. ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 52 U.S. VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 U.S. CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 55 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 56 U.S. RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 57 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 58 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 59 CANADA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 CANADA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 CANADA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 CANADA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 CANADA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 CANADA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 CANADA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 CANADA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 CANADA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 68 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 69 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 70 CANADA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 71 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 72 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 73 MEXICO THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 74 MEXICO GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 MEXICO NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 MEXICO DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 MEXICO CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 78 MEXICO RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 MEXICO ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 MEXICO VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 MEXICO CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 82 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 83 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 84 MEXICO RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 85 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 86 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 87 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 88 EUROPE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 89 EUROPE GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 90 EUROPE NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 91 EUROPE DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 EUROPE CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 93 EUROPE RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 94 EUROPE ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 95 EUROPE VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 96 EUROPE CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 97 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 98 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 99 EUROPE RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 100 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 101 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 102 GERMANY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 103 GERMANY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 104 GERMANY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 105 GERMANY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 106 GERMANY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 107 GERMANY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 108 GERMANY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 109 GERMANY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 110 GERMANY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 111 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 112 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 113 GERMANY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 114 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 115 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 116 FRANCE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 117 FRANCE GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 118 FRANCE NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 119 FRANCE DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 120 FRANCE CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 121 FRANCE RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 122 FRANCE ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 123 FRANCE VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 124 FRANCE CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 125 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 126 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 127 FRANCE RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 128 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 129 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 130 U.K. THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 131 U.K. GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 132 U.K. NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 133 U.K. DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 134 U.K. CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 135 U.K. RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 136 U.K. ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 137 U.K. VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 138 U.K. CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 139 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 140 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 141 U.K. RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 142 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 143 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 144 RUSSIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 145 RUSSIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 146 RUSSIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 147 RUSSIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 148 RUSSIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 149 RUSSIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 150 RUSSIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 151 RUSSIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 152 RUSSIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 153 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 154 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 155 RUSSIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 156 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 157 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 158 ITALY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 159 ITALY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 160 ITALY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 161 ITALY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 162 ITALY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 163 ITALY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 164 ITALY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 165 ITALY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 166 ITALY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 167 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 168 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 169 ITALY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 170 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 171 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 172 SPAIN THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 173 SPAIN GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 174 SPAIN NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 175 SPAIN DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 176 SPAIN CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 177 SPAIN RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 178 SPAIN ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 179 SPAIN VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 180 SPAIN CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 181 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 182 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 183 SPAIN RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 184 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 185 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 186 NETHERLAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 187 NETHERLAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 188 NETHERLAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 189 NETHERLAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 190 NETHERLAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 191 NETHERLAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 192 NETHERLAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 193 NETHERLAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 194 NETHERLAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 195 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 196 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 197 NETHERLAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 198 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 199 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 200 SWITZERLAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 201 SWITZERLAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 202 SWITZERLAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 203 SWITZERLAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 204 SWITZERLAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 205 SWITZERLAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 206 SWITZERLAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 207 SWITZERLAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 208 SWITZERLAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 209 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 210 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 211 SWITZERLAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 212 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 213 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 214 POLAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 215 POLAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 216 POLAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 217 POLAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 218 POLAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 219 POLAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 220 POLAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 221 POLAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 222 POLAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 223 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 224 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 225 POLAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 226 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 227 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 228 TURKEY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 229 TURKEY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 230 TURKEY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 231 TURKEY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 232 TURKEY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 233 TURKEY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 234 TURKEY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 235 TURKEY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 236 TURKEY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 237 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 238 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 239 TURKEY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 240 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 241 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 242 AUSTRIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 243 AUSTRIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 244 AUSTRIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 245 AUSTRIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 246 AUSTRIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 247 AUSTRIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 248 AUSTRIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 249 AUSTRIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 250 AUSTRIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 251 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 252 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 253 AUSTRIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 254 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 255 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 256 HUNGARY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 257 HUNGARY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 258 HUNGARY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 259 HUNGARY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 260 HUNGARY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 261 HUNGARY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 262 HUNGARY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 263 HUNGARY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 264 HUNGARY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 265 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 266 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 267 HUNGARY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 268 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 269 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 270 NORWAY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 271 NORWAY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 272 NORWAY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 273 NORWAY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 274 NORWAY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 275 NORWAY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 276 NORWAY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 277 NORWAY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 278 NORWAY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 279 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 280 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 281 NORWAY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 282 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 283 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 284 IRELAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 285 IRELAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 286 IRELAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 287 IRELAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 288 IRELAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 289 IRELAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 290 IRELAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 291 IRELAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 292 IRELAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 293 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 294 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 295 IRELAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 296 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 297 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 298 LITHUANIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 299 LITHUANIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 300 LITHUANIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 301 LITHUANIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 302 LITHUANIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 303 LITHUANIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 304 LITHUANIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 305 LITHUANIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 306 LITHUANIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 307 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 308 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 309 LITHUANIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 310 REST OF EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 311 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 312 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 313 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 314 ASIA-PACIFIC THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 315 ASIA-PACIFIC GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 316 ASIA-PACIFIC NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 317 ASIA-PACIFIC DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 318 ASIA-PACIFIC CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 319 ASIA-PACIFIC RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 320 ASIA-PACIFIC ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 321 ASIA-PACIFIC VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 322 ASIA-PACIFIC CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 323 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 324 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 325 ASIA-PACIFIC RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 326 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 327 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 328 CHINA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 329 CHINA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 330 CHINA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 331 CHINA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 332 CHINA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 333 CHINA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 334 CHINA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 335 CHINA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 336 CHINA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 337 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 338 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 339 CHINA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 340 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 341 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 342 JAPAN THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 343 JAPAN GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 344 JAPAN NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 345 JAPAN DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 346 JAPAN CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 347 JAPAN RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 348 JAPAN ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 349 JAPAN VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 350 JAPAN CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 351 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 352 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 353 JAPAN RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 354 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 355 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 356 INDIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 357 INDIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 358 INDIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 359 INDIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 360 INDIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 361 INDIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 362 INDIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 363 INDIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 364 INDIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 365 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 366 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 367 INDIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 368 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 369 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 370 SOUTH KOREA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 371 SOUTH KOREA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 372 SOUTH KOREA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 373 SOUTH KOREA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 374 SOUTH KOREA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 375 SOUTH KOREA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 376 SOUTH KOREA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 377 SOUTH KOREA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 378 SOUTH KOREA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 379 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 380 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 381 SOUTH KOREA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 382 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 383 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 384 AUSTRALIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 385 AUSTRALIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 386 AUSTRALIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 387 AUSTRALIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 388 AUSTRALIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 389 AUSTRALIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 390 AUSTRALIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 391 AUSTRALIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 392 AUSTRALIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 393 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 394 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 395 AUSTRALIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 396 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 397 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 398 SINGAPORE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 399 SINGAPORE GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 400 SINGAPORE NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 401 SINGAPORE DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 402 SINGAPORE CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 403 SINGAPORE RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 404 SINGAPORE ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 405 SINGAPORE VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 406 SINGAPORE CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 407 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 408 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 409 SINGAPORE RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 410 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 411 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 412 THAILAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 413 THAILAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 414 THAILAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 415 THAILAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 416 THAILAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 417 THAILAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 418 THAILAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 419 THAILAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 420 THAILAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 421 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 422 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 423 THAILAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 424 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 425 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 426 INDONESIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 427 INDONESIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 428 INDONESIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 429 INDONESIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 430 INDONESIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 431 INDONESIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 432 INDONESIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 433 INDONESIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 434 INDONESIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 435 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 436 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 437 INDONESIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 438 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 439 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 440 PHILIPPINES THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 441 PHILIPPINES GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 442 PHILIPPINES NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 443 PHILIPPINES DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 444 PHILIPPINES CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 445 PHILIPPINES RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 446 PHILIPPINES ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 447 PHILIPPINES VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 448 PHILIPPINES CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 449 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 450 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 451 PHILIPPINES RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 452 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 453 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 454 MALAYSIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 455 MALAYSIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 456 MALAYSIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 457 MALAYSIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 458 MALAYSIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 459 MALAYSIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 460 MALAYSIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 461 MALAYSIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 462 MALAYSIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 463 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 464 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 465 MALAYSIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 466 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 467 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 468 VIETNAM THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 469 VIETNAM GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 470 VIETNAM NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 471 VIETNAM DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 472 VIETNAM CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 473 VIETNAM RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 474 VIETNAM ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 475 VIETNAM VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 476 VIETNAM CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 477 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 478 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 479 VIETNAM RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 480 REST OF ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 481 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 482 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 483 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 484 SOUTH AMERICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 485 SOUTH AMERICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 486 SOUTH AMERICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 487 SOUTH AMERICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 488 SOUTH AMERICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 489 SOUTH AMERICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 490 SOUTH AMERICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 491 SOUTH AMERICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 492 SOUTH AMERICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 493 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 494 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 495 SOUTH AMERICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 496 BRAZIL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 497 BRAZIL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 498 BRAZIL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 499 BRAZIL GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 500 BRAZIL NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 501 BRAZIL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 502 BRAZIL CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 503 BRAZIL RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 504 BRAZIL ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 505 BRAZIL VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 506 BRAZIL CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 507 BRAZIL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 508 BRAZIL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 509 BRAZIL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 510 ARGENTINA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 511 ARGENTINA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 512 ARGENTINA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 513 ARGENTINA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 514 ARGENTINA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 515 ARGENTINA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 516 ARGENTINA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 517 ARGENTINA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 518 ARGENTINA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 519 ARGENTINA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 520 ARGENTINA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 521 ARGENTINA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 522 ARGENTINA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 523 ARGENTINA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 524 PERU LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 525 PERU LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 526 PERU THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 527 PERU GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 528 PERU NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 529 PERU DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 530 PERU CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 531 PERU RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 532 PERU ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 533 PERU VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 534 PERU CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 535 PERU LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 536 PERU LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 537 PERU RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 538 REST OF SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 539 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 540 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 541 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 542 MIDDLE EAST AND AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 543 MIDDLE EAST AND AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 544 MIDDLE EAST AND AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 545 MIDDLE EAST AND AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 546 MIDDLE EAST AND AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 547 MIDDLE EAST AND AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 548 MIDDLE EAST AND AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 549 MIDDLE EAST AND AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 550 MIDDLE EAST AND AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 551 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 552 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 553 MIDDLE EAST AND AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 554 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 555 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 556 SOUTH AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 557 SOUTH AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 558 SOUTH AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 559 SOUTH AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 560 SOUTH AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 561 SOUTH AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 562 SOUTH AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 563 SOUTH AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 564 SOUTH AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 565 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 566 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 567 SOUTH AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 568 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 569 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 570 SAUDI ARABIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 571 SAUDI ARABIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 572 SAUDI ARABIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 573 SAUDI ARABIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 574 SAUDI ARABIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 575 SAUDI ARABIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 576 SAUDI ARABIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 577 SAUDI ARABIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 578 SAUDI ARABIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 579 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 580 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 581 SAUDI ARABIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 582 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 583 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 584 U.A.E THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 585 U.A.E GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 586 U.A.E NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 587 U.A.E DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 588 U.A.E CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 589 U.A.E RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 590 U.A.E ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 591 U.A.E VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 592 U.A.E CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 593 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 594 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 595 U.A.E RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 596 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 597 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 598 ISRAEL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 599 ISRAEL GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 600 ISRAEL NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 601 ISRAEL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 602 ISRAEL CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 603 ISRAEL RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 604 ISRAEL ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 605 ISRAEL VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 606 ISRAEL CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 607 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 608 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 609 ISRAEL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 610 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 611 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 612 EGYPT THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 613 EGYPT GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 614 EGYPT NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 615 EGYPT DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 616 EGYPT CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 617 EGYPT RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 618 EGYPT ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 619 EGYPT VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 620 EGYPT CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 621 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 622 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 623 EGYPT RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 624 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 625 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 626 KUWAIT THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 627 KUWAIT GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 628 KUWAIT NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 629 KUWAIT DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 630 KUWAIT CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 631 KUWAIT RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 632 KUWAIT ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 633 KUWAIT VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 634 KUWAIT CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 635 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 636 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 637 KUWAIT RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 638 REST OF MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

그림 목록

FIGURE 1 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION

FIGURE 2 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: END USER GRID

FIGURE 9 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION

FIGURE 11 RISING GOVERNMENT AWARENESS PROGRAMS ABOUT THE INHERITED RETINAL DISEASE IS EXPECTED TO DRIVE THE GLOBAL LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INFANTILE TYPE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL LEBER CONGENITAL AMAUROSIS MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET IN LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE GLOBAL LEBER CONGENITAL AMAUROSIS MARKET

FIGURE 16 PROPORTION OF RPE65 GENE MUTATION IN CLINICALLY DIAGNOSED LCA PATIENTS

FIGURE 17 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2021

FIGURE 18 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)

FIGURE 19 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, CAGR (2022-2029)

FIGURE 20 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 21 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2021

FIGURE 22 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 23 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 24 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 25 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2021

FIGURE 26 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 27 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 28 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE

FIGURE 29 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 30 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 31 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 32 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE

FIGURE 33 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)

FIGURE 34 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY REGION (2021)

FIGURE 35 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY REGION (2022 & 2029)

FIGURE 36 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY REGION (2021 & 2029)

FIGURE 37 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)

FIGURE 38 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)

FIGURE 39 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)

FIGURE 40 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 41 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 42 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)

FIGURE 43 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)

FIGURE 44 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)

FIGURE 45 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 46 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 47 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)

FIGURE 48 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)

FIGURE 49 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)

FIGURE 50 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 51 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 52 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)

FIGURE 53 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)

FIGURE 54 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)

FIGURE 55 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 56 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 57 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)

FIGURE 58 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)

FIGURE 59 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)

FIGURE 60 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 61 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 62 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)

FIGURE 63 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)

FIGURE 64 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)

FIGURE 65 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)

FIGURE 66 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The growth rate of the leber congenital amaurosis market is 4.8% in the forecast by 2029.
Europe is expected to dominate the leber congenital amaurosis market due to an increase in technological advancement in the developing areas.
The major companies in the leber congenital amaurosis market are Invitae Corporation, Spark Therapeutics, Inc., LKC Technologies, CENTOGENE N.V., Optos, Metrovision, Blue Print Genetics Oy (A Subsidiary of Quest Diagnostics), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio, Inc. , Atsena Therapeutics, Editas Medicine, Eluminex Biosciences, Okuvision, Astellas Pharma Inc., Allergan, agtc, Gyroscope Therapeutics Limited, SparingVision, Kubota Pharmaceutical Holdings Co. Ltd., REGENXBIO Inc. among others.
Disease type, type, end-user, and distribution channel are the factors on which the leber congenital amaurosis market research is based.
An increase in the incidence and prevalence of rpe65 gene-mediated in retinal diseases & increase in pipeline products and clinical trials are the growth drivers of the leber congenital amaurosis market.

관련 페이지 탐색

Banner